Caris Life Sciences
- Market cap
- 7.66B
- P/E (TTM)i
- 72.85
- P/Bi
- 12.94
- EPSi
- -1.90
- Div yieldi
- 0.00%
- 52W posi
- 66%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.2 percentage points.
Institutional ownership
- Held by institutions
- 60.92% +0.20pp
- Institutions
- 296 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-05-15
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| David Halbert | Chairman, CEO & Founder | 43.39% |
| Peter Castleman | Lead Independent Director | 3.77% |
| Jon Halbert | Director | 0.52% |
| David Spetzler | President | 0.42% |
| Brian Brille | Executive Vice Chairman & Executive VP | 0.19% |
| George Poste | Vice Chairperson | 0.19% |
| Laurie Johansen | Independent Director | 0.11% |
| Jonathan Kenneth Knowles | Independent Vice Chairperson | 0.10% |
| T. Phillips | -- | 0.04% |
| J. Denton | Senior Vice President | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-21 | J. Denton | Senior Vice President | Open Market Disposition | -7,500 | $31.82 |
| 2026-09-16 | Brian Brille | Executive Vice Chairman & Executive VP | Derivative Exercise and Sale | -400,000 | $2.44–30.33 |
| 2026-09-03 | David Spetzler | President | Derivative Exercise and Sale | -597,212 | $2.44–25.32 |
| 2026-09-03 | David Spetzler | President | Derivative Exercise and Retained | +652,788 | $2.44 |
| 2026-09-03 | David Spetzler | President | Intent to Sell (Form 144) | -119,212 | $24.76 |
| 2026-09-02 | David Spetzler | President | Intent to Sell (Form 144) | -478,000 | $24.86 |
| 2026-08-13 | Peter Castleman | Lead Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Jon Halbert | Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | T. Phillips | -- | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Laurie Johansen | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Lloyd Minor | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | David Fredrickson | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Jeffrey Vacirca | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Joseph Gilliam | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-06 | George Poste | Vice Chairperson | Intent to Sell (Form 144) | -30,000 | $21.42 |
| 2026-08-02 | George Poste | Vice Chairperson | Intent to Sell (Form 144) | -20,000 | $16.25 |
| 2026-05-28 | George Poste | Vice Chairperson | Other Acquisition | +1,600 | $15.62 |
| 2026-05-28 | Jonathan Kenneth Knowles | Independent Vice Chairperson | Other Acquisition | +1,600 | $15.62 |
| 2026-05-14 | David Halbert | Chairman, CEO & Founder | Sale to Issuer | -40,712 | $15.25 |
| 2026-05-14 | Jon Halbert | Director | Open Market Acquisition | +68,000 | $14.56 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:29:27 · For reference only, not investment advice and not tailored to your situation.